MoonLake Immunotherapeutics (MLTX) Net Cash Flow (2021 - 2026)
MoonLake Immunotherapeutics (MLTX) posted quarterly Net Cash Flow of -$35.5 million for Q1 2026, down 138.96% year-over-year from $91.2 million in Q1 2025, and down 117.93% quarter-over-quarter from -$16.3 million in Q4 2025.
MoonLake Immunotherapeutics (MLTX) Net Cash Flow (2021 - 2026) Analysis & Trends
MoonLake Immunotherapeutics' Net Cash Flow history runs 6 years deep, the most recent figure standing at -$35.5 million for Q1 2026.
- In Q1 2026, Net Cash Flow fell 138.96% year-over-year to -$35.5 million; the TTM figure through Mar 2026 stood at $26.2 million (up 114.03% YoY), while the FY2025 annual figure was $153.0 million, up 156.48% from the prior year.
- Net Cash Flow for Q1 2026 stood at -$35.5 million, down from -$16.3 million in the prior quarter.
- The five-year high for Net Cash Flow was $451.8 million in Q2 2023, with the low at -$195.7 million in Q4 2024.
- The 5-year median for Net Cash Flow is $7.2 million (2024), against an average of $17.0 million.
- The sharpest annual moves came in 2022 and 2023: Net Cash Flow plunged 3266.85% in 2022, then soared 7962.69% in 2023.
- MoonLake Immunotherapeutics' Net Cash Flow stood at -$1.7 million in 2022, then jumped by 7962.69% to $132.9 million in 2023, then slumped by 247.18% to -$195.7 million in 2024, then surged by 91.66% to -$16.3 million in 2025, then sank by 117.93% to -$35.5 million in 2026.
- Business Quant data shows MLTX's Net Cash Flow at -$35.5 million in Q1 2026, -$16.3 million in Q4 2025, and $44.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | MoonLake Immunotherapeutics | 1.40 Bn | 864.68 Mn | - | 179.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 179.39 Mn |
| Jun 30, 2026 | 179.39 Mn |
| Mar 31, 2026 | -35.54 Mn |
| Mar 31, 2026 | -35.54 Mn |
| Dec 31, 2025 | -16.31 Mn |
| Dec 31, 2025 | -16.31 Mn |
| Sep 30, 2025 | 44.34 Mn |
| Sep 30, 2025 | 44.34 Mn |
| Jun 30, 2025 | 33.72 Mn |
| Jun 30, 2025 | 33.72 Mn |
| Mar 31, 2025 | 91.23 Mn |
| Mar 31, 2025 | 91.23 Mn |
| Dec 31, 2024 | -195.65 Mn |
| Dec 31, 2024 | -195.65 Mn |
| Sep 30, 2024 | 33.19 Mn |
| Sep 30, 2024 | 33.19 Mn |
| Jun 30, 2024 | -115.63 Mn |
| Jun 30, 2024 | -115.63 Mn |
| Mar 31, 2024 | 7.23 Mn |
| Mar 31, 2024 | 7.23 Mn |